|
|
 |
Dear Reader,
In this month’s newsletter, the Foundation is proud to announce the preliminary program and roster of speakers, moderators and discussion panelists for our upcoming 2nd International Symposium on Focused Ultrasound. As you will quickly see, this three-day program is steadily evolving into an exciting, landmark event – one exclusively devoted to leading edge research and development in our innovative and immensely promising field.
Between now and the symposium’s start on October 17, the Foundation will be providing regular updates regarding speakers, topics, sponsors and more via this newsletter, special emails and press releases. We invite you to follow along via Facebook and Twitter.
While the Foundation is abuzz with symposium planning, our work of advocating for collaboration and supporting research continues.
In this newsletter, we announce the launch of our newest strategic initiative: Focused Ultrasound-mediated Targeted Drug Delivery (FUS-TDD). Now in its initial stages, FUS-TDD has begun developing a group of highly-influential core stakeholders. Ultimately, the initiative will foster collaborations to accelerate development of new, minimally-invasive alternatives to chemotherapy and similar treatments.
On the research front, we share the results of preclinical experiments in prostate cancer treatment performed by one of our funded researchers, Lili Chen, Ph.D. We also welcome three leading researchers – Katherine Whittaker Ferrara, Ph.D., Graeme Houston, M.D. and Ernst Martin, M.D. – to our independent advisory committees. |
Excitement is building for the 2nd International Symposium on MR-guided Focused Ultrasound, scheduled for October 17 through 20 in Washington, D.C. 
Friends of the Foundation can now receive updates via 
Findings recently reported by Lili Chen, Ph.D., Associate Professor and a medical physicist in the Radiation Oncology Department of Fox Chase Cancer Center in Philadelphia, indicate that MR-guided focused ultrasound has the potential to increase the efficacy of docetaxel in treating prostate cancer. Supported by a Foundation research award totaling $102,324, Chen set out to answer two key questions: 
